Holen Sie sich die Stockscreener-App
62.23
0.95%
-0.60
Handel nachbörslich:
63.08
0.85
+1.37%
Schlusskurs vom Vortag:
$62.83
Offen:
$62.98
24-Stunden-Volumen:
2.64M
Relative Volume:
1.00
Marktkapitalisierung:
$15.42B
Einnahmen:
$2.38B
Nettoeinkommen (Verlust:
$833.42M
KGV:
20.63
EPS:
3.0172
Netto-Cashflow:
$917.69M
1W Leistung:
+3.96%
1M Leistung:
+9.60%
6M Leistung:
+40.22%
1J Leistung:
+58.71%
1-Tages-Spanne:
$61.74
$63.39
1-Wochen-Bereich:
$58.59
$63.39
52-Wochen-Spanne:
$33.76
$63.39
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
62.23 | 15.42B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2026-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2026-06-25 | Fortgesetzt | Truist | Hold |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
2 Under-the-Radar Stocks to Buy and Hold - The Motley Fool
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Zacks Investment Research
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 - BioSpace
Exelixis to release Q3FY26 results on Oct 29, 2026 - scanx.trade
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again - Zacks Investment Research
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance Singapore
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - Morningstar
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm - TradingView
Exelixis Inc stock hits all-time high at 61.21 USD - Investing.com
Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com South Africa
Exelixis Inc stock hits all-time high at 61.21 USD By Investing.com - Investing.com India
Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital - ChartMill
Virtus NFJ Mid-Cap Value Fund's Exelixis Inc(EXEL) Holding History - GuruFocus
Exelixis (NasdaqGS:EXEL) Stock Price - Simply Wall Street
Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says - marketscreener.com
RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating - Yahoo Finance
EXEL Maintained by RBC Capital -- Price Target Lowered to $45 - GuruFocus
Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance
Exelixis stock gets a higher Truist target at USD 54 - AD HOC NEWS
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus - Yahoo Finance
Is Exelixis Stock Engineered To Make You Money? - Yahoo Finance
Is Exelixis Stock Engineered To Make You Money? - Trefis
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Owning the Improvement Is Not Freedom to Operate: Exelixis v. MSN Shows the Reach of Earlier Genus Patents - The National Law Review
Owning the Improvement Is Not Freedom to Operate: Exelixis v. MSN Shows the Reach of Earlier Genus Patents - The National Law Review
Exelixis delays cancer-drug review: what it means for Exelixis stock - AD HOC NEWS
Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK
Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup - ChartMill
Exelixis, Inc. - Simply Wall Street
Exelixis, Inc. Podcast | EXEL Podcasts & Related Content - finance.biggo.com
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis Shares Rising on CABOMETYX Revenue - Yahoo Finance
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com Nigeria
Exelixis stock hits all-time high at 59.73 USD - Investing.com
Exelixis stock hits all-time high at 59.73 USD By Investing.com - Investing.com South Africa
Exelixis (EXEL) is a Top-Ranked Growth Stock: Should You Buy? - Zacks Investment Research
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Exelixis, Inc. (EXEL) Stock forecasts - au.finance.yahoo.com
Cash flow from operating activities of Exelixis, Inc. – HAN:EX9 - TradingView
Return on equity % of Exelixis, Inc. – HAN:EX9 - TradingView
Exelixis (NasdaqGS:EXEL) Stock Forecast & Analyst Predictions - Simply Wall Street
Exelixis, Inc. (EXEL) Stock forecasts - sg.finance.yahoo.com
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? - TradingView
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo! Finance Canada
Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - easternprogress.com
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exelixis Inc-Aktie (EXEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MARY BECKERLE | Director |
Aug 10 '26 |
Proposed Sale |
53.66 |
9,812 |
526,496 |
0 |
| JACK L WYSZOMIERSKI | Director |
Jun 01 '26 |
Proposed Sale |
50.55 |
3,925 |
198,409 |
0 |
| Eckhardt Sue Gail | Director |
Jun 01 '26 |
Sale |
50.14 |
9,812 |
491,974 |
16,079 |
| WYSZOMIERSKI JACK L | Director |
Jun 01 '26 |
Sale |
50.55 |
3,925 |
198,409 |
284,384 |
| Eckhardt Sue Gail | Director |
Jun 01 '26 |
Proposed Sale |
50.87 |
9,812 |
499,136 |
0 |
| Aftab Dana | EVP, Research and Development |
May 26 '26 |
Sale |
50.35 |
43,451 |
2,187,758 |
594,741 |
| DANA T AFTAB | Officer |
May 26 '26 |
Proposed Sale |
50.35 |
43,451 |
2,187,758 |
0 |
| PATRICK JOSEPH HALEY | Officer |
May 20 '26 |
Proposed Sale |
49.81 |
32,110 |
1,599,444 |
0 |
| Haley Patrick J. | EVP, Commercial |
May 20 '26 |
Sale |
49.81 |
32,110 |
1,599,399 |
357,638 |
| BRENDA JOY HEFTI | Officer |
May 18 '26 |
Proposed Sale |
50.21 |
6,625 |
332,641 |
0 |
0.60%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):